A specialty pharmaceutical company, Oculus Innovative Sciences, Inc., has introduced two new MicrocynAH Farm and Ranch animal healthcare products for care of traumatic wounds, cuts abrasions, skin irritations, skin ulcers, post-surgical incisions, burns, scratches, rashes and irritated skin. Both the MicrocynAH Farm and Ranch spray and the MicrocynAH Farm and Ranch hydrogel are manufactured with the original patented Microcyn Technology.
Oculus has partnered with SLA Brands, one of the animal healthcare industry's premier sales organizations in the United States and Canada, to bring the MicrocynAH products, including the new farm and ranch offerings, to market.
"The line extension of the MicrocynAH animal healthcare products into farm and ranch is simply the next logical step," said Michael Lasky, a partner in SLA Brands. "MicrocynAH's ability to help create an optimal wound healing environment without the use of antibiotics is most noteworthy, better enabling farmers and ranchers to support President Obama's five-year plan to fight the threat posed by antibiotic-resistant bacteria."
The first US animal healthcare products included multiple sizes of the MicrocynAH wound & skin care liquids, MicrocynAH wound & skin care hydrogels, MicrocynAH pink eye spray, MicrocynAH eye and ear wash and MicrocynAH ophthalmic gel.
According to the Freedonia Group, an international industry market research firm, the demand for animal health products in the United States is forecast to increase 3.9% annually to $12.7 billion in 2016. Animal healthcare is a relatively recession-resistant industry as it is regarded as a necessary expense of animal ownership or husbandry. Furthermore, as pet owners increasingly treat their companion animals as members of the family, pets' lifespans will continue to lengthen, driving strong sales of health products.
Oculus Innovative Sciences is a specialty pharmaceutical company that develops and markets solutions for the treatment of dermatological conditions and advanced tissue care. The company's products, which are sold throughout the United States and internationally, have improved outcomes for more than five million patients globally by reducing infections, itch, pain, scarring and harmful inflammatory responses.